ITMI20070084A1 - LIPID BASED VAGINAL ANTISEPTIC DEVICES - Google Patents

LIPID BASED VAGINAL ANTISEPTIC DEVICES Download PDF

Info

Publication number
ITMI20070084A1
ITMI20070084A1 ITMI20070084A ITMI20070084A1 IT MI20070084 A1 ITMI20070084 A1 IT MI20070084A1 IT MI20070084 A ITMI20070084 A IT MI20070084A IT MI20070084 A1 ITMI20070084 A1 IT MI20070084A1
Authority
IT
Italy
Prior art keywords
mcfa
acid
monoglyceride
vaginal
unsaturated
Prior art date
Application number
Other languages
Italian (it)
Inventor
Carlo Ghisalberti
Original Assignee
Carlo Ghisalberti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlo Ghisalberti filed Critical Carlo Ghisalberti
Priority to ITMI20070084 priority Critical patent/ITMI20070084A1/en
Priority to PCT/IB2008/000135 priority patent/WO2008090440A1/en
Publication of ITMI20070084A1 publication Critical patent/ITMI20070084A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Description

DESCRIZIONE DESCRIPTION

DISPOSITIVI ANTISETTICI VAGINALI A BASE LIPIDICA LIPID-BASED VAGINAL ANTISEPTIC DEVICES

CAMPO DELL’INVENZIONE FIELD OF THE INVENTION

Composizioni e metodi di trattamento delle vaginosi infettive, in particolare delle candidosi, mediante dispostivi (es ovuli) vaginali a basso impatto psicologico e tossicologico. Compositions and methods of treatment of infectious vaginosis, in particular candidiasis, by means of vaginal devices (eg ovules) with a low psychological and toxicological impact.

TECNICA ANTERIORE FRONT TECHNIQUE

Le infezioni vaginali, dette anche vaginiti o vaginosi, sono infezioni della vagina causate da uno o più agenti infettivi, identificabili in microrganismi patogeni di diverso genere. Vaginal infections, also called vaginitis or vaginosis, are infections of the vagina caused by one or more infectious agents, identifiable in pathogenic microorganisms of different kinds.

Nel caso dì perdite vaginali grigiastre e con cattivo odore la causa frequente sono batteri del tipo Gardnerella vaginalis o anaerobi come Bacteroides e Peptococcits , Mobiluncus spp. e Bacteroides spp. La terapia prevede in genere l’uso di metronidazolo o clindamicìna. In the case of greyish and bad-smelling vaginal discharge, the frequent cause are bacteria of the Gardnerella vaginalis type or anaerobes such as Bacteroides and Peptococcits, Mobiluncus spp. and Bacteroides spp. Therapy generally involves the use of metronidazole or clindamycin.

Per perdite biancastre e dense con prurito intenso, generalmente si tratta dì un'infezione da Candida, più frequentemente Candida albicans , sebbene stiano intensificandosi le infezioni da C. tropicalis e C. glabrata che, purtroppo, presentano maggiore resistenza alla terapia antimicotica. La terapia farmacologica si avvale di derivati azotici e ciclopirox olamina per via topica, oppure di lcetoconazolo, fluconazolo o itraconazolo per via sistemica. For whitish and dense discharge with intense itching, it is generally a Candida infection, more frequently Candida albicans, although infections with C. tropicalis and C. glabrata are intensifying and, unfortunately, are more resistant to antifungal therapy. Pharmacological therapy uses azotic derivatives and ciclopirox olamine topically, or lcetoconazole, fluconazole or itraconazole systemically.

Nel caso di perdite giallastre con prurito e spesso con bruciore intenso si può sospettare la presenza di un'infezione da Trichomonas vaginalis, un protozoo di solito trasmesso per via sessuale. La terapia, più comune è con metronidazolo, preferibilmente estesa anche al partner. Numerose dorme rifiutano, e pertanto non si sottopongono a trattamenti anti-infettivi a causa della resistenza psicologica e culturale all’uso di farmaci. In the case of yellowish discharge with itching and often with intense burning, the presence of an infection with Trichomonas vaginalis, a usually sexually transmitted protozoan, may be suspected. The most common therapy is with metronidazole, preferably also extended to the partner. Many sleepers refuse, and therefore do not undergo anti-infective treatments due to psychological and cultural resistance to the use of drugs.

E’ tuttavia noto che un’infezione vaginale non trattata è dannosa e persino pericolosa in quanto ad esempio può rendere la vagina suscettibile all’infezione HIV e pone a rischio il feto in dorme in gravidanza. Per questo motivo è interessante introdurre sistemi terapeutici con basso impatto tossicologico e tossicologico, pur mantenendo un elevata efficienza antibiotica. Ad esempio è noto che gli lipidi a catena medio-corta e ì loro gliceridi posseggono azione biocida (Kabara et all.'. U.S. 4,002,775). However, it is known that an untreated vaginal infection is harmful and even dangerous as, for example, it can make the vagina susceptible to HIV infection and puts the sleeping fetus in pregnancy at risk. For this reason it is interesting to introduce therapeutic systems with low toxicological and toxicological impact, while maintaining a high antibiotic efficiency. For example, it is known that medium-short chain lipids and their glycerides possess biocidal action (Kabara et al. U.S. 4,002,775).

La capacità biocide della monolaurina in virus (es. Hemophihis influenza) è stata descritta da Isaacs et all. Antimicrob Agents Chemother. 1987 Jan;31(l):27-3 1. La monolaurina è inoltre attiva in numerosi patogeni tra cui Siaphylococcus epidermis e S. aureus, Streptococci-grampositivi Streptococcus agalactiae , Listerìa monocytogenes, e vari gram-negativi quali Vibrìo pcirahaemoìyticus e Helicobacter pylori , o su protozoi e miceti quali la Candida albicam. L’attività biocida dell’acido caprico e monoglicerìde è stata studiata da Bergsson e coll, in Appi Environ Microbiol. 2006; 72(l):522-6 ( Campylobacter jejuni, Salmonella spp., and Escherichia coli)·, Int J Antimicrob Agents. 2002; 20(4): 258-62. {Helicobacter pilori ), APMIS. 2001; 109(10): 670-8 (gram+ Cocci),' Antimicrob Agents Chemother. 1999; 43(1 1):2790-2. (Neisseiia gonorrhoeae), Antimicrob Agents Chemother. 1998; 42(9):2290-4 (Chlamydia trachomatis). The biocidal capacity of monolaurin in viruses (eg Hemophihis influenza) has been described by Isaacs et all. Antimicrob Agents Chemother. 1987 Jan; 31 (l): 27-3 1. Monolaurin is also active in numerous pathogens including Siaphylococcus epidermis and S. aureus, Streptococci-gram-positive Streptococcus agalactiae, Listerìa monocytogenes, and various gram-negative ones such as Vibrìo pcirahaemoìyticus and Helicobacter pylori , or on protozoa and fungi such as Candida albicam. The biocidal activity of capric acid and monoglyceride was studied by Bergsson and coll, in Appi Environ Microbiol. 2006; 72 (l): 522-6 (Campylobacter jejuni, Salmonella spp., And Escherichia coli) ·, Int J Antimicrob Agents. 2002; 20 (4): 258-62. {Helicobacter pylori), APMIS. 2001; 109 (10): 670-8 (gram + Cocci), 'Antimicrob Agents Chemother. 1999; 43 (1 1): 2790-2. (Neisseiia gonorrhoeae), Antimicrob Agents Chemother. 1998; 42 (9): 2290-4 (Chlamydia trachomatis).

Composizioni topiche contenenti monocaprina comprendono una crema virucìda (Pharmazie. Topical compositions containing monocaprin comprise a virucid cream (Pharmazie.

2005; 60(12): 897-9); un dissinfettante dentale (Acta Odontol Scand. 2006; 64(l):21-6), un idrogel antimicrobico (DrugDevInd Pharm. 2003; 29(2):121-9). 2005; 60 (12): 897-9); a dental disinfectant (Acta Odontol Scand. 2006; 64 (l): 21-6), an antimicrobial hydrogel (DrugDevInd Pharm. 2003; 29 (2): 121-9).

Un idrogai a base di monocaprina è stato sviluppato da Neyts J et all. (J Med Virol. 2000; 61(1): 107-10) per la prevenzione dell’infezione vaginale da HTV. A monocaprin-based hydrogai was developed by Neyts J et all. (J Med Virol. 2000; 61 (1): 107-10) for the prevention of vaginal HTV infection.

E’ invece sorprendente notare che queste ed altre ricerche (Antimicrob Agents Chemother. Instead, it is surprising to note that these and other researches (Antimicrob Agents Chemother.

2001, 45(11), 3209-12) nella quale si evidenzia una discreta attività degli acidi caprico e laurico nei confronti della C. albiccms, non abbiano dato seguito operativo. 2001, 45 (11), 3209-12) in which a fair activity of capric and lauric acids is highlighted against C. albiccms, have not given any operational follow-up.

Si ritiene l’utilizzo di formulazioni composite, generalmente in forma di emulsione, risultino essere sub-inibitorie rispetto all’azione biocida nelle condizioni di utilizzo in vivo. The use of composite formulations, generally in the form of emulsion, is believed to be sub-inhibitory with respect to the biocidal action in the conditions of use in vivo.

Rimane di vasto interesse introdurre in ginecologia dei sistemi antibiotici a basso impatto tossicologico e psicologico pur caratterizzati da elevata efficienza, richiesta tuttora inesaudita. It remains of great interest to introduce antibiotic systems with a low toxicological and psychological impact in gynecology, albeit characterized by high efficiency, a request still unfulfilled.

SOMMARIO SUMMARY

Si contempla un dispositivo vaginale utile nel trattamento delle vaginosi infettive, essenzialmente formato da MCFA o loro monogliceridi, in grado rilasciare in loco una quantità da 6 a 24 mmoli di detti MCFA o loro monogliceridi. Particolarmente preferito è un tale dispositivo in forma di ovulo vaginale con punto di fusione compreso tra 31 ,5 e 37,5°C. A vaginal device useful in the treatment of infectious vaginosis is contemplated, essentially formed by MCFA or their monoglycerides, capable of releasing on site a quantity from 6 to 24 mmoles of said MCFA or their monoglycerides. Particularly preferred is such a device in the form of a vaginal ovum with a melting point between 31.5 and 37.5 ° C.

Si contampla inoltre un dispositivo vaginale comprendente MCFA o loro monogliceridi ed uno o più ingredienti scelti tra: (b) un lipide C8-C12 non- irritante; (b’) un terpene o un (alchìl)fenolo non- irritante; (b”) un antimi co tico/antibiotico. Also included is a vaginal device comprising MCFA or their monoglycerides and one or more ingredients selected from: (b) a non-irritating C8-C12 lipid; (b ') a non-irritating terpene or (alkyl) phenol; (b ”) an antimictic / antibiotic.

Un oggetto inventivo è peraltro l’uso di MCFA per il trattamento delle vaginosi infettive, in particolare candidosi vaginali, senza l’ausilio o con quantità ridotte di antibiotici. An inventive object is, however, the use of MCFA for the treatment of infectious vaginosis, in particular vaginal candidiasis, without the aid or with reduced amounts of antibiotics.

DESCRIZIONE DETTAGLIATA DELL’INVENZIONE DETAILED DESCRIPTION OF THE INVENTION

Un oggetto inventivo è un dispositivo vaginale utile nel trattamento delle vaginosi infettive essenzialmente formato da acidi grassi a catena media (MCFA) o loro monogliceridi in grado rilasciare una quantità da 6 a 24 mmoli di MCFA, detto MCFA scelto tra: An inventive object is a vaginal device useful in the treatment of infectious vaginosis essentially formed by medium chain fatty acids (MCFA) or their monoglycerides capable of releasing a quantity from 6 to 24 mmoles of MCFA, called MCFA chosen from:

Caprylic (octanoic) acid: CAS 124-07-2; p.f. 15-17°C ; MW 144,21 Caprylic (octanoic) acid: CAS 124-07-2; m.p. 15-17 ° C; MW 144.21

Pelargonio (nonanoic) acid: CAS 112-05-0; p.f. 9-11°C; MW 158.24 Pelargonium (nonanoic) acid: CAS 112-05-0; m.p. 9-11 ° C; MW 158.24

Capric (decanoic) acid: CAS 334^48-5 ; p.f. 31-33°C; MW 172.1 Capric (decanoic) acid: CAS 334 ^ 48-5; m.p. 31-33 ° C; MW 172.1

Undecanoic acid: CAS 112-37-8; p.f. 28-31°C; MW 186.29 Undecanoic acid: CAS 112-37-8; m.p. 28-31 ° C; MW 186.29

Lauric (dodecanoic) acid: CAS 143-07-7; p.f. 43-45°C ; MW 200.3 Lauric (dodecanoic) acid: CAS 143-07-7; m.p. 43-45 ° C; MW 200.3

Gli MCFA sono fomiti ad esempio da: Universal Preserv-A-Chem, Ine.; A&E Connock, Aceto Corp; Akzo Nobel; Alfa Pharmachem; Berje; Cognis; DeWolf Chemical; Fleurchem; Penta Manufacturing; Spectrum Chemical Mfg.; Uniqema; Beckman Chemikalìen; CasChem; Merck Schuchard, Protameen Chemicals; Stearinerie Dubois Fils. MCFAs are supplied for example by: Universal Preserv-A-Chem, Ine .; A&E Connock, Aceto Corp; Akzo Nobel; Alfa Pharmachem; Berje; Cognis; DeWolf Chemical; Fleurchem; Penta Manufacturing; Spectrum Chemical Mfg .; Uniqema; Beckman Chemikalien; CasChem; Merck Schuchard, Protameen Chemicals; Stearinerie Dubois Fils.

Preferibilmente il dispositivo della presente invenzione comprenderà almeno un MCFA scelto tra acido caprico e acido laurico. Preferably the device of the present invention will comprise at least one MCFA selected from capric acid and lauric acid.

I monogliceridi di MCFA sono scelti tra uno o più delle seguenti sostanze: MCFA monoglycerides are selected from one or more of the following substances:

Glyceril captate (monocaprin) CAS 26402-22-2 ; p.f. 17.8°C ; MW 246.34 Glyceril captate (monocaprin) CAS 26402-22-2; m.p. 17.8 ° C; MW 246.34

Glyceril laurate (monolaurin) CAS 27215-38-4 / 142-18-7 ; p.f. 56-60°C; MW 274.21 Sono inoltre compresi i monogliceridi formati da acidi grassi C8-C12 diversi da caprico e laurico ottenuti mediante per condensazione con glicerina con uno o più acidi grassi saturi o insaturi, lineari o ramificati scelti tra quelli precedentemente descritti. Glyceril laurate (monolaurin) CAS 27215-38-4 / 142-18-7; m.p. 56-60 ° C; MW 274.21 Also included are monoglycerides formed by C8-C12 fatty acids other than capric and lauric obtained by condensation with glycerin with one or more saturated or unsaturated, linear or branched fatty acids selected from those previously described.

Monocaprina e monolaurina sono fomiti ad esempio da: A & E Connock; Abitec Corp; Dr. Straetmans; Inolex Chemical; Stearinerie Dubois; Taiyo Kagaku; Cognis; Croda Chemicals; DeWolf Chemical; Fitz Cbem Corp; Jeen International; Med-Chem Labs; Protameen Chemicals; Sasol; Stepan Company; Ultra Chemical; Uniqema; Universal Preserv-A-Chem. Preferibilmente il dispositivo della presente invenzione comprenderà almeno un monogliceride di un MCFA scelto tra monocaprina e monolaurina. Monocaprine and monolaurin are supplied for example by: A & E Connock; Abitec Corp; Dr. Straetmans; Inolex Chemical; Stearinerie Dubois; Taiyo Kagaku; Cognis; Croda Chemicals; DeWolf Chemical; Fitz Cbem Corp; Jeen International; Med-Chem Labs; Protameen Chemicals; Sasol; Stepan Company; Ultra Chemical; Uniqema; Universal Preserv-A-Chem. Preferably, the device of the present invention will comprise at least one monoglyceride of an MCFA selected from monocaprin and monolaurin.

Un ulteriore oggetto inventivo è costituito da un dispositivo vaginale utile nel trattamento delle vaginosi infettive comprendente: A further inventive object is constituted by a vaginal device useful in the treatment of infectious vaginosis comprising:

(a) un MCFA o loro loro monogliceridi; (a) an MCFA or their monoglycerides thereof;

(b) un lipide C8-C12 non-irritante scelto tra: (b) a non-irritating C8-C12 lipid chosen from:

(bl) un carbossilato C8-C12 insaturo e/o ramificato; (b1) an unsaturated and / or branched C8-C12 carboxylate;

(b2) un acido idrossammico C8-C12; (b2) a C8-C12 hydroxamic acid;

(b3) un aldeide C8-C12 satura o insatura, lineare o ramificata; (b3) a saturated or unsaturated, linear or branched C8-C12 aldehyde;

(b4) un alcol C8-C12 saturo o insaturo, lineare o ramificato; (b4) a saturated or unsaturated, linear or branched C8-C12 alcohol;

(b5) un estere gallico di un alcol C8-C12 saturo o insaturo, lineare o ramificato; detto dispositivo in grado rilasciare in loco una quantità da 6 a 24 mmoli di MCFA-equivalenti in forma di ovulo o di capsula di gelatina molle. (b5) a gallic ester of a saturated or unsaturated, linear or branched C8-C12 alcohol; said device capable of delivering on site a quantity of from 6 to 24 mmoles of MCFA-equivalents in the form of an egg or a soft gelatin capsule.

Esempi di (bl) in nomenclatura intemazionale sono: 2-Methylheptanoic acid; 4-Methylnonanoic acid; Methyloctanoic acid; Dec-9-enoic acid; Dec-(5-,6)-enoic acid; Dec-2-enoic acid; Dec-3-enoic acid; Dec-4-enoic acid; 2-Ethylhexanoic acid; 4-EthyIoctanoic acid; 4-Methyldecanoic acid; 8-Methyldecanoic acid; Non-2-enoic acid; Non-3-enoic acid; Octenoic acid; Methylheptanoic acid. Examples of (bl) in international nomenclature are: 2-Methylheptanoic acid; 4-Methylnonanoic acid; Methyloctanoic acid; Dec-9-enoic acid; Dec- (5-, 6) -enoic acid; Dec-2-enoic acid; Dec-3-enoic acid; Dec-4-enoic acid; 2-Ethylhexanoic acid; 4-EthyIoctanoic acid; 4-Methyldecanoic acid; 8-Methyldecanoic acid; Non-2-enoic acid; Non-3-enoic acid; Octenoic acid; Methylheptanoic acid.

Il dispositivo della presente invenzione potrà comprendere un carbossilato C8-C12 insaturo e/o ramificato (bl) purché non-irritante. E' pertanto da usare con cautela l’acido 10-undecenoico (undecylenic acid) in quanto si registrano precedenti di effetti allergizzanti (Contact Dermatitis. 2002, 46(2): 109). The device of the present invention may comprise an unsaturated and / or branched C8-C12 carboxylate (bl) provided it is non-irritating. Therefore, 10-undecenoic acid (undecylenic acid) should be used with caution as there are precedents of allergenic effects (Contact Dermatitis. 2002, 46 (2): 109).

Gli acidi idrossammici (b2) sono scelti tra i derivati da un acido carbossilico (o suo estere) C8-C12 di tipo saturo o insaturo, lineare o ramificato, ottenuti mediante conversione del gruppo carbossile CO-OH in CO-NHOH. The hydroxamic acids (b2) are selected from the derivatives of a C8-C12 carboxylic acid (or its ester) of the saturated or unsaturated type, linear or branched, obtained by converting the CO-OH carboxyl group into CO-NHOH.

Il dispositivo della presente invenzione potrà comprendere un acido ìdrossammico C8-C12 saturo o insaturo, lineare o ramificato (b2) purché non-irritante. Sono preferiti l’acido decilidrossamico ( CH3(CH2)8CO-NHOH ) e rottilidrossammico ( CH3(CH2)<;CO-NHOH ). Esempi di (b3) in nomenclatura intemazionale sono: Octanal; Decanal; Dodecanal; 3,7-Dimethyl-7-hydroxyoctanal; 2,6-DìmethyloctanaI; 2-Methyloctanal; Nonanal; 2-Ethylhept-2-enal, Undecanal, 10-Undecenal; 9-Undecenal; 2-Dodecenal; i-2,c-6-Nonadienal; c-6-Nonenal; 2-Octenal; 6-Octenal; 2,4-Nonadienal; /-2-Nonenal; 2,6-DLmethylhept-S-enal, 2-Decenal; 2-Methylundecanal; 2,4-Decadienal; c-4 -Decenai; 2-isopropyl-5-methylhex-2-enal; 2,4-Undecadienal; 2-Undecenal; 2-trans,6-t-Octadienal; 4-Hexenal; c-4-Decenal; 9-Decenal; 2-t Dodecenal; 2-Ethylhexanal; 2-Methyldecanal; 2-Methylhexanal; 2-NonenaI; 2-i,6-/-Nonadienal, 2-/-Undecenal; 2,4-Octadienal; t-2-Octenal; /-2-Decenal; i-2,M-Nonadienal;1-2, t-A-Undecadienal; /-2,M,c-7-Decatrienal; 9-Octadecenal; c-9-Decenal; /-6-Decenal; 5-Decenal.Il dispositivo della presente invenzione potrà comprendere un aldeide C8-C12 satura o insatura, lineare o ramificata, purché non-irritante. The device of the present invention may comprise a saturated or unsaturated C8-C12 hydroxamic acid, linear or branched (b2) provided it is non-irritating. Decylhydroxamic (CH3 (CH2) 8CO-NHOH) and rottylhydroxamic (CH3 (CH2) <; CO-NHOH) acid are preferred. Examples of (b3) in international nomenclature are: Octanal; Decanal; Dodecanal; 3,7-Dimethyl-7-hydroxyoctanal; 2,6-DìmethyloctanaI; 2-Methyloctanal; Nonanal; 2-Ethylhept-2-enal, Undecanal, 10-Undecenal; 9-Undecenal; 2-Dodecenal; i-2, c-6-Nonadienal; c-6-Nonenal; 2-Octenal; 6-Octenal; 2,4-Nonadienal; / -2-Nonenal; 2,6-DLmethylhept-S-enal, 2-Decenal; 2-Methylundecanal; 2,4-Decadienal; c-4 -Decenai; 2-isopropyl-5-methylhex-2-enal; 2,4-Undecadienal; 2-Undecenal; 2-trans, 6-t-Octadienal; 4-Hexenal; c-4-Decenal; 9-Decenal; 2-t Dodecenal; 2-Ethylhexanal; 2-Methyldecanal; 2-Methylhexanal; 2-NonenaI; 2-i, 6 - / - Nonadienal, 2 - / - Undecenal; 2,4-Octadienal; t-2-Octenal; / -2-Decenal; i-2, M-Nonadienal; 1-2, t-A-Undecadienal; / -2, M, c-7-Decatrienal; 9-Octadecenal; c-9-Decenal; / -6-Decenal; The device of the present invention may comprise a saturated or unsaturated, linear or branched C8-C12 aldehyde, provided it is non-irritating.

Esempi di (b4) in nomenclatura intemazionale sono: c-3-Octen-l-ol, c-5-Octen-l-ol;/- 2-Octen-l-ol; 3,5-Octadien-l-ol; c-2-Nonen-l-ol; /-2-Nonen-l-ol; c-6-Nonen-l-ol, c-3-Nonenl-ol; 2,6-Nonadien-l-oI; 2,4-Nonadien-l-ol; 3,6-Nonadien-l-ol; /-2,c-6-Nonadien-l-ol; t-3,c-6-Nonadien-I-ol; 2,4-Decadien-l-ol; t-2-Decen-l-ol; 2-Undecen-l-ol; 9-Decen-l-ol, 10-Undecen-l-ol; Octan-2-ol; Octan-3-ol; 2,6-Dimethylheptan-4-ol; 2-Ethylhexan-l-ol; Nonan-2-ol; Nonan-3-ol; 2-Methyloctan-l-ol; 3,5,5-Trimethylhexan-l-ol; Decan-3-ol, 3,6-Dimethyloctan-3-ol; Undecan-2-ol; Dodecan-2-ol; 2-Octen-4-ol; 6-Methylhept-5-en-2-ol; 1-Nonen-3-ol, l-Decen-3-ol; l-Octen-3-ol; 3-Octen-2-ol; l,5-Octadien-3-ol, 2,6-Dimethylhept-6-en-l-ol; (-)-3,7-Dimethyl-6-octen-l-ol; 2,6-Dimethyloct-7-en-2-oI; 2,6-Dimethylocta-l,5,7-trien-3-ol; 3,7-Dimethylocta-l,5,7-trien-3-ol; l,5-Undecadien-3-ol; /-2-Octen- 1 -ol, c-3-Octenl-ol; c-5-Octen-l-ol; c-2-Nonen-l-ol; i-2-Nonen-l-ol; c-6-Nonen-l-ol; c-3-Nonen-l-ol, t-2-Decen-l-ol; c-4-Decen-l-ol; 2-Undecen-l-ol; 10-Undecenol; n-Octanol; n-Nonanol; n-Decanol, n-UndecanoI; n-Dodecanol. Examples of (b4) in international nomenclature are: c-3-Octen-1-ol, c-5-Octen-1-ol; / - 2-Octen-1-ol; 3,5-Octadien-1-ol; c-2-Nonen-1-ol; / -2-Nonen-1-ol; c-6-Nonen-1-ol, c-3-Nonen-1-ol; 2,6-Nonadien-1-oI; 2,4-Nonadien-1-ol; 3,6-Nonadien-1-ol; / -2, c-6-Nonadien-1-ol; t-3, c-6-Nonadien-I-ol; 2,4-Decadien-1-ol; t-2-Decen-1-ol; 2-Undecen-1-ol; 9-Decen-1-ol, 10-Decen-1-ol; Octan-2-ol; Octan-3-ol; 2,6-Dimethylheptan-4-ol; 2-Ethylhexan-1-ol; Nonan-2-ol; Nonan-3-ol; 2-Methyloctan-1-ol; 3,5,5-Trimethylhexan-1-ol; Decan-3-ol, 3,6-Dimethyloctan-3-ol; Undecan-2-ol; Dodecan-2-ol; 2-Octen-4-ol; 6-Methylhept-5-en-2-ol; 1-Nonen-3-ol, 1-Decen-3-ol; 1-Octen-3-ol; 3-Octen-2-ol; 1,5-Octadien-3-ol, 2,6-Dimethylhept-6-en-1-ol; (-) - 3,7-Dimethyl-6-octen-1-ol; 2,6-Dimethyloct-7-en-2-oI; 2,6-Dimethylocta-1, 5,7-trien-3-ol; 3,7-Dimethylocta-1, 5,7-trien-3-ol; 1,5-Undecadien-3-ol; / -2-Octen- 1 -ol, c-3-Octenl-ol; c-5-Octen-1-ol; c-2-Nonen-1-ol; i-2-Nonen-1-ol; c-6-Nonen-1-ol; c-3-Nonen-1-ol, t-2-Decen-1-ol; c-4-Decen-1-ol; 2-Undecen-1-ol; 10-Undecenol; n-Octanol; n-Nonanol; n-Decanol, n-UndecanoI; n-Dodecanol.

Il dispositivo della presente invenzione potrà comprendere almeno un alcol C8-C12 saturo o insaturo, lineare o ramificato, purché non-irritante. The device of the present invention may comprise at least one saturated or unsaturated C8-C12 alcohol, linear or branched, as long as it is non-irritating.

Gli esteri gallici (b5) sono scelti tra i derivati di un alcol C8-C12 saturo o insaturo, lineare o ramificato ottenuti mediante condensazione con l’acido gallico e detto alcol. Gallic esters (b5) are selected from the derivatives of a saturated or unsaturated, linear or branched C8-C12 alcohol obtained by condensation with gallic acid and said alcohol.

Il dispositivo della presente invenzione potrà comprendere un estere gallico di un alcol saturo o insaturo, lineare o ramificato (b5) purché non-irritante. Sono preferiti l’ottil gallato e il dodecil gallato, con qualche cautela a causa di qualche segnalazione di effetto allergizzante. The device of the present invention may comprise a gallic ester of a saturated or unsaturated alcohol, linear or branched (b5) as long as it is non-irritating. Octyl gallate and dodecyl gallate are preferred, with some caution due to some reports of an allergenic effect.

Un ulteriore oggetto inventivo è costituito da un dispositivo vaginale utile nel trattamento delle vaginosi infettive comprendente: A further inventive object is constituted by a vaginal device useful in the treatment of infectious vaginosis comprising:

(a) un MCFA o loro loro monogliceridi, (a) an MCFA or their monoglycerides,

(b’) un terpene o un (alchil)fenolo non-irritante scelto tra: (b ') a terpene or a non-irritating (alkyl) phenol chosen from:

(b’I) un terpene a funzione alcolica; (b'I) a terpene with an alcoholic function;

(b’2) un terpene a funzione carbonilica; (b2) a terpene with a carbonyl function;

(b’3) un terpene (ciclo)alifatico saturo o insaturo, (b'3) a saturated or unsaturated aliphatic terpene (cycle),

(b’4) un fenolo compreso nell’elenco degli aromi; (b'4) a phenol included in the list of flavors;

(b’5) un ossialchilbenzene compreso nell’elenco degli aromi; (b'5) an oxyalkylbenzene included in the list of flavors;

detto dispositivo in grado rilasciare in loco una quantità da 6 a 24 mmoli di MCFA-equivalentì in fonma di ovulo o di capsula di gelatina molle. said device capable of delivering on site a quantity of from 6 to 24 mmoles of MCFA-equivalent in the form of an egg or soft gelatin capsule.

Il dispositivo della presente invenzione potrà comprendere un terpene a funzione alcolica, purché non-irritante. The device of the present invention may comprise a terpene with an alcoholic function, provided it is non-irritating.

Esempi di (b’1) in nomenclatura internazionale sono: R-(+)-3-CitroneUol; cis-Nerol; Dehydrolinalool; 1,2-Dihydrylinlool; Tetrahydrolinalool; Tetrahydrogeranol; Phytol; Isophytol, cis-Nerolidol, trans-Nerolidol; Myrcenol; Dihydomyercenol; Tetrahydromyercenol; Lavandulol; 1-Menthol; d,l-Menthol; p-Mentha-l,8-dien-7-ol; p-Menthan-8-ol; Carvomenthol, d-Neomenthol; Isopulegol; Piperitol; Homomenthol; Carveol; Dihydrocarveol; neo-Dihydrocarveol; Isodihydrocarveol; Pine hexanol; a-Terpineol; β-Terpineol; 1-Terpineol, Carvomenthenol, (±)-a-Bisabolol; Isobomol; α-Fenchol; 2-Ethylfenchol; trans, trans-Famesol; cis-2-Pananol; 4-Thujanol; cis-Pinocarveol; cis-Myrtanol; trans-Myrtanol; Myrtenol; Verbenol, Vetiverol; 9-Cedrenol; 2-Cedren-15-ol; Cedrol; Caryophyllol; α-lonol; β-Ιο<η>οί; b-Dihydroionol; Nopol; Cedanol; α-Camphol; β- e a-Santalol. Examples of (b'1) in international nomenclature are: R - (+) - 3-CitroneUol; cis-Nerol; Dehydrolinalool; 1,2-Dihydrylinlool; Tetrahydrolinalool; Tetrahydrogeranol; Phytol; Isophytol, cis-Nerolidol, trans-Nerolidol; Myrcenol; Dihydomyercenol; Tetrahydromyercenol; Lavandulol; 1-Menthol; d, l-Menthol; p-Mentha-1,18-dien-7-ol; p-Menthan-8-ol; Carvomenthol, d-Neomenthol; Isopulegol; Piperitol; Homomenthol; Carveol; Dihydrocarveol; neo-Dihydrocarveol; Isodihydrocarveol; Pine hexanol; a-Terpineol; β-Terpineol; 1-Terpineol, Carvomenthenol, (±) -a-Bisabolol; Isobomol; α-Fenchol; 2-Ethylfenchol; trans, trans-Famesol; cis-2-Pananol; 4-Thujanol; cis-Pinocarveol; cis-Myrtanol; trans-Myrtanol; Myrtenol; Verbenol, Vetiverol; 9-Cedrenol; 2-Cedren-15-ol; Cedrol; Caryophyllol; α-lonol; β-Ιο <η> οί; b-Dihydroionol; Nopol; Cedanol; α-Camphol; β- and a-Santalol.

11 dispositivo della presente invenzione potrà comprendere un terpene a funzione carbonilica, purché non-irritante. The device of the present invention may comprise a terpene with a carbonyl function, provided it is non-irritating.

Esempi di (b’2) in nomenclatura intemazionale sono: Citral; Citrone; Carvomenthenal; Safranal; Myrtenal; β-Homocyclocitral; 3,5,5-Trimethylhexanal; Perillaldehyde, a-Campholenic aldehyde; Photocitral A; α-Sinensal; p-Mentha-l,3-dien-7-al; Famesal; Isocyclocitral; Nera!; Pseudo-cyclocitral; β-Sinensal; Geranial; α-Methyl ional; α-Ionone; β-Ionone; Methyl-a-ionone; Methyl-β-ionone; a-Irone; Carvone; Isojasmone; Tetramethyl ethylcyclohexenone; α-Isomethyl ionone; β-Isomethylionone; p-Menthan-3-one; Allyl aionone; Isopulegone; Tetrahydro-pseudo-ionone; 3,4-Dimethylcyclopentan-l,2-dione; d,l-Isomenthone; β-Damascone; Methyl-5-ionone; Nootkatone; γ-Ionone; Carvomenthone, cis-Jasmone; β-Damascenone; 4-Ketoisophorone; Famesyl acetone; 3,4-Dehydrodihydro-betaionone; Geranylacetone; Tsophorone; Piperìtenone; Dihydrocarvone; delta-Damascone, DihydΓO-β-ionone; Dihydro-alpha-ionone; Celestolide; α-Damascone; Dihydrojasmone, Acetylcedrene; d-Carvone; 1-Carvone; 11,10-Dihydronootkatone; Hexahydropseudoionone; d-Fenchone; 2-Hydroxypiperitone; β-Ionone epoxide; Isopinocamphone, Cryptone; Megastigma-4,6,8-trien-3-one; Megastigma-5,8-dien-4-one; Piperitone; trans-Menthone, Verbenone; Pseudo-ionone; 6-Methyl^-ionone; d-Camphor; trans-Jasmone; cis^-Damascone; cis-alpha-Damascone; trans-alpha-Damascone; α-Damascenone; trans-6-Damascone Examples of (b'2) in international nomenclature are: Citral; Citron; Carvomenthenal; Safranal; Myrtenal; β-Homocyclocitral; 3,5,5-Trimethylhexanal; Perillaldehyde, a-Campholenic aldehyde; Photocitral A; α-Sinensal; p-Mentha-1,3-dien-7-al; Famesal; Isocyclocitral; Black!; Pseudo-cyclocitral; β-Sinensal; Geranial; α-Methyl ional; α-Ionone; β-Ionone; Methyl-a-ionone; Methyl-β-ionone; heron; Carvone; Isojasmone; Tetramethyl ethylcyclohexenone; α-Isomethyl ionone; β-Isomethylionone; p-Menthan-3-one; Allyl aionone; Isopulegone; Tetrahydro-pseudo-ionone; 3,4-Dimethylcyclopentan-1,2-dione; d, l-Isomenthone; β-Damascone; Methyl-5-ionone; Nootkatone; γ-Ionone; Carvomenthone, cis-Jasmone; β-Damascenone; 4-Ketoisophorone; Famesyl acetone; 3,4-Dehydrodihydro-betaionone; Geranylacetone; Tsophorone; Pipertenone; Dihydrocarvone; delta-Damascone, DihydΓO-β-ionone; Dihydro-alpha-ionone; Celestolide; α-Damascone; Dihydrojasmone, Acetylcedrene; d-Carvone; 1-Carvone; 11,10-Dihydronootkatone; Hexahydropseudoionone; d-Fenchone; 2-Hydroxypiperitone; β-Ionone epoxide; Isopinocamphone, Cryptone; Megastigma-4,6,8-trien-3-one; Megastigma-5,8-dien-4-one; Piperitone; trans-Menthone, Verbenone; Pseudo-ionone; 6-Methyl ^ -ionone; d-Camphor; trans-Jasmone; cis ^ -Damascone; cis-alpha-Damascone; trans-alpha-Damascone; α-Damascenone; trans-6-Damascone

0 dispositivo della presente invenzione potrà comprendere un fenolo compreso tra l’elenco degli aromi, purché non-irritante. The device of the present invention may include a phenol included in the list of aromas, as long as it is non-irritating.

Esempi di (b’4) in nomenclatura intemazionale sono: Phenol; 4-Syringol; 4-Hydroxybenzol; Eugenol; Isoeugenol; Gauacol; Thymol; 2-Methoxy-4-methylphenol; 4-Ethylguaiacol; 2-Methoxy-4-vinylphenol; 2,5-Dimethylphenol; 3,5-DimethylphenoI; 3-Ethylphenol, 4-Ethylphenol; o-Cresol; m-Cresol; p-Cresol; Carvacrol; Syringol; 4-Ethoxyphenol; Phenol; Salieoi; Methyl salieoi; 2,6-Hylenol; o-Cumenol; 2-(Ethoxymethyl)phenol, 2-Propylphenol; 3,4-Xyleno!; 2-Methoxy^4-propylphenol; 4-Propylphenol; 4-Methoxyeugenol, 4-Ethylsyringol; 4-Methylsyringol; Fragarol; 4-PropenylsyringoI; 4-Propylsyringol, 4-Viny!phenol; 4-tert Butylphenol; Hydroxyanisol gaUate, 2,3-Xylenol; 2,4-Xylenol; Phlorol; 3-Isopropylphenol; 4-Isopropylphenol; 6-tert-Butyl-m-cresol; 5-Methylguaiacol; 2,3,6-Trimethylphenol; 2-Methoxy-6-(2-propeny)phenol; Vanitici; Ethyl vanillol. Examples of (b'4) in international nomenclature are: Phenol; 4-Syringol; 4-Hydroxybenzol; Eugenol; Isoeugenol; Gauacol; Thymol; 2-Methoxy-4-methylphenol; 4-Ethylguaiacol; 2-Methoxy-4-vinylphenol; 2,5-Dimethylphenol; 3,5-DimethylphenoI; 3-Ethylphenol, 4-Ethylphenol; o-Cresol; m-Cresol; p-Cresol; Carvacrol; Syringol; 4-Ethoxyphenol; Phenol; Salieoi; Methyl salieoi; 2,6-Hylenol; o-Cumenol; 2- (Ethoxymethyl) phenol, 2-Propylphenol; 3,4-Xyleno !; 2-Methoxy ^ 4-propylphenol; 4-Propylphenol; 4-Methoxyeugenol, 4-Ethylsyringol; 4-Methylsyringol; Fragarol; 4-PropenylsyringoI; 4-Propylsyringol, 4-Viny! Phenol; 4-tert Butylphenol; Hydroxyanisol gaUate, 2,3-Xylenol; 2,4-Xylenol; Phlorol; 3-Isopropylphenol; 4-Isopropylphenol; 6-tert-Butyl-m-cresol; 5-Methylguaiacol; 2,3,6-Trimethylphenol; 2-Methoxy-6- (2-propeny) phenol; Vanitics; Ethyl vanillol.

II d<i>spositivo della presente invenzione potrà comprendere un ossialchilbenzene compreso tra l’elenco degli aromi, purché non-irri tante. The device of the present invention may include an oxyalkylbenzene included in the list of flavors, provided that it is not irrelevant.

Esempi di (b’5) in nomenclatura intemazionale sono: Benzol; 2-Phenylethan-l-ol; 3-Phenylpropan- 1 -ol; 1-Pheny<]>propan- l-ol; l-Phenylpentan-2-ol; 2-Methyl-l -phenylpropan-2-ol, 4-Phenylbutan-2-ol; 3-Methyl-l-phenylpentan-3-ol; 4-Phenylbutan-l-oI; Cuminol, p-Cymen-8-ol; 5-PhenyIpentan-l-ol; 1-Phenylethan-l-ol; 4-Methyl-I-phenylpentan-2-ol; 4-Phenylbut-3-en-2-ol; Hydratropol; 2-MethyI-4-phenylbutan-2-ol; p-Aniso); 3-(4-Methoxypbenyl)propan-l-ol; 2-Phenylpropan-2-ol; Piperò noi; Benzaldehyde; Cinnamaldehyde; 4-Methoxybenzaldehyde, Piperonal;Veratraldehyde; VaniUin; Salicyladehyde; Vanillyl acetone, Methyl 2-naphthyl ketone; 4-Methylacetophenone; 2,4-Dimethylacetophenone; 4-Phenylbut-3-en-2-one; 4-Methyl-l-phenylpentan-2-one; 4-(p-Tolyl)butan-2-one; Benzoin; Raspberry ketone. Examples of (b'5) in international nomenclature are: Benzol; 2-Phenylethan-1-ol; 3-Phenylpropan- 1 -ol; 1-Pheny <]> propan-1-ol; 1-Phenylpentan-2-ol; 2-Methyl-1 -phenylpropan-2-ol, 4-Phenylbutan-2-ol; 3-Methyl-1-phenylpentan-3-ol; 4-Phenylbutan-1-oI; Cuminol, p-Cymen-8-ol; 5-PhenyIpentan-1-ol; 1-Phenylethan-1-ol; 4-Methyl-I-phenylpentan-2-ol; 4-Phenylbut-3-en-2-ol; Hydratropol; 2-MethyI-4-phenylbutan-2-ol; p-Aniso); 3- (4-Methoxypbenyl) propan-1-ol; 2-Phenylpropan-2-ol; I will pee us; Benzaldehyde; Cinnamaldehyde; 4-Methoxybenzaldehyde, Piperonal; Veratraldehyde; VaniUin; Salicyladehyde; Vanillyl acetone, Methyl 2-naphthyl ketone; 4-Methylacetophenone; 2,4-Dimethylacetophenone; 4-Phenylbut-3-en-2-one; 4-Methyl-1-phenylpentan-2-one; 4- (p-Tolyl) butan-2-one; Benzoin; Raspberry ketone.

Un ulteriore oggetto inventivo è costituito da un dispositivo vaginale utile nel trattamento delle vaginosi infettive comprendente: A further inventive object is constituted by a vaginal device useful in the treatment of infectious vaginosis comprising:

(a) un MCFA o loro loro monogliceridi; (a) an MCFA or their monoglycerides thereof;

(b”) un antimicotico/antibiotico; (b ”) an antifungal / antibiotic;

in grado rilasciare in loco una quantità da 6 a 24 mmoli di MCFA; ed inoltre contenente una quantià sub-inibitoria di antimicotico (b”); detto dispositivo in forma di ovulo o di capsula di gelatina molle. capable of releasing on site a quantity of 6 to 24 mmoles of MCFA; and also containing a sub-inhibitory quantity of antifungal (b "); said device in the form of an egg or a soft gelatin capsule.

Gli antimicotici (b”) utilizzabili nella presente invenzione comprendono: azolici, ad es. ketoconazolo, miconazolo, bifonazolo, butoconazolo, clotrimazolo, croconazolo, eberconazolo, econazolo, oxiconazolo, fenticonazolo, isoconazolo, sulconazolo, triconazolo, lanoconazolo, neticonazolo, omoconazolo, setraconazolo; albi ami ne, ad es. terbinafina e natrifina, morfoline, ad es. amorfolina, polieni, ad es. amfoteracina B, nistatina e natamaicina; idrossipiridinoti, ad es. ciclopirox olamina, octopirox olamina e rilopirox.; furatici ad es.metronidazolo e nitrofurazone, The antifungals (b ") usable in the present invention include: azoles, e.g. ketoconazole, miconazole, bifonazole, butoconazole, clotrimazole, croconazole, eberconazole, econazole, oxiconazole, fenticonazole, isoconazole, sulconazole, triconazole, lanoconazole, nethiconazole, homoconazole, setraconazole; albi ami ne, eg. terbinafine and natrifine, morpholines, eg. amorpholine, polyenes, e.g. amphoteracin B, nystatin and natamaicin; hydroxypyridinotes, e.g. ciclopirox olamine, octopirox olamine and rilopirox .; furatics e.g. metronidazole and nitrofurazone,

Ulteriori antimi colici (b”) utilizzabili nella presente invenzione comprendono: flucitosina,griseofulvina, butenafina, clioquinolo, aloprogina, to In aitato, violetto di genziana, potassio permanganato, SeS, sali e complessi d’argento, zinco piritione, betulina, oli essenziali quali tea tree oil, eucaliptolo, ecc. bacitracina, clindamicina, eritromicina, gentamicina, mupirocina, neomicina, tetraciclina, polimixina B, benzalcotio cloruro e altri ammoni quaternari,esaclorofene, iodio, iodoquinolo, mafetide, sali di mercurio. Further antimicrobials (b ") that can be used in the present invention include: flucytosine, griseofulvin, butenafine, clioquinol, aloprogin, nitrogen, gentian violet, potassium permanganate, SeS, silver salts and complexes, zinc pyrithione, betulin, essential oils such as tea tree oil, eucalyptol, etc. bacitracin, clindamycin, erythromycin, gentamicin, mupirocin, neomycin, tetracycline, polymyxin B, benzalcothium chloride and other quaternary ammones, hexachlorophene, iodine, iodoquinol, mafetide, mercury salts.

Gli ingredienti addizionali nel dispositivo della presente invenzione sono contenuti preferibilmente in quantità non superiore al 30% in peso e comprendono tra l’altro, in forma non esaustiva, vaselina, petrolato, mono- e di-gliceridi semisintetici C14-C18, glicerina, lecitina, cetostearyl alcool; polyethyleneglycol; polyethyleneglycol stearate, propylenglycol; polysorbate 20, metilcellulosa ed altri esteri ed eteri della cellulosa; conservanti come metil, etil and propil parabene, sodio benzoato; oli vegetali e acidi grassi da oli vegetali; e oli essenziali. Un ulteriore oggetto inventivo è costituito da una ovulo vaginale in grado rilasciare in costituita essenzialmente da MCFA, da soli o in combinazione, contenente inoltre un olio essenziale quali lavanda, eucaliptolo, tea tree oil o tra quelli contenenti carvacrolo e cimenolo (majorana, origano, santoreggia e timo). I MCFA o loro monogliceridi presenti da soli o in associazione con uno o più ingrediente (b), (c) e (d), costituiscono almeno il 70% in peso, preferibilmente il 80% in peso, ancora più preferibilmente il 90% in peso del dispositivo. The additional ingredients in the device of the present invention are preferably contained in quantities not exceeding 30% by weight and include, inter alia, in non-exhaustive form, petroleum jelly, petrolatum, C14-C18 semisynthetic mono- and di-glycerides, glycerin, lecithin , cetostearyl alcohol; polyethyleneglycol; polyethyleneglycol stearate, propylenglycol; polysorbate 20, methylcellulose and other cellulose esters and ethers; preservatives such as methyl, ethyl and propyl paraben, sodium benzoate; vegetable oils and fatty acids from vegetable oils; and essential oils. A further inventive object is constituted by a vaginal ovum capable of releasing essentially consisting of MCFA, alone or in combination, also containing an essential oil such as lavender, eucalyptol, tea tree oil or among those containing carvacrol and cimenol (majorana, oregano, savory and thyme). The MCFAs or their monoglycerides present alone or in association with one or more ingredients (b), (c) and (d), constitute at least 70% by weight, preferably 80% by weight, even more preferably 90% by weight weight of the device.

Un altro oggetto inventivo è costituito dal metodo di produzione di un ovulo vaginale mediante miscelazione di MCFA, da soli o in combinazione, eventualmente parzialmente neutralizzati, opzionalmente con minime quantità di ingredienti addizionali, ad ottenere una ovulo vaginale con p.f. compreso tra 31,5 e 37,5°C, preferibilmente 32-36°C. Another inventive object is constituted by the method of producing a vaginal ovum by mixing MCFA, alone or in combination, possibly partially neutralized, optionally with minimal quantities of additional ingredients, to obtain a vaginal ovum with m.p. between 31.5 and 37.5 ° C, preferably 32-36 ° C.

Un ulteriore oggetto inventivo è l’uso di MCFA per il trattamento delle vaginosi infettive, in particolare delle candidosi vaginali in assenza di agenti biocidi (tipicamente antimicotici) o in presenza di quantità sub-inibitorie degli stessi, come nelPesempio a seguire.A further inventive object is the use of MCFA for the treatment of infectious vaginosis, in particular of vaginal candidiasis in the absence of biocidal agents (typically antifungals) or in the presence of sub-inhibitory quantities thereof, as in the following example.

Gli esempi a seguire sono illustrativi e non devono essere considerati come limitanti.The examples below are illustrative and should not be regarded as limiting.

ESEMPI EXAMPLES

Esempio 1 - Miscela per ovuli composte da acido caprico e acidn laurino Example 1 - Mixture for ova composed of capric acid and laurine acid

Le miscele binarie tra acido caprico e acido laurico sono state prodotte per ottenere l’intervallo di punti di fusione utile per la preparazione di una ovulo costitituita da questi due ingredienti. The binary mixtures between capric acid and lauric acid were produced to obtain the range of melting points useful for the preparation of an egg made up of these two ingredients.

La figura 1 mostra il diagramma di fase in funzione della temperatura dove L = stato liquido, M = stato in fusione e S = stato solido. L’intervallo utile è costituito da acido caprico-acìdo laurico in proporzione tra 1 :4 a 1 :5 in peso. Figure 1 shows the phase diagram as a function of temperature where L = liquid state, M = melting state and S = solid state. The useful range consists of capric acid-lauric acid in a proportion between 1: 4 to 1: 5 by weight.

Esempio 2 - Miscela per ovuli composte da acido laurico e monolaurina Example 2 - Mixture for ova composed of lauric acid and monolaurin

Miscele binarie tra acido caprico e acido laurico sono state prodotte per ottenere Γ intervallo di punti di fusione utile per la preparazione di una ovulo costitituita da questi due ingredienti. La figura 2 mostra il diagramma di fase, laddove l’intervallo utile è costituito da acido laurico e monolaurina in proporzione tra 3:2 a 4:1 in peso. Binary mixtures between capric acid and lauric acid have been produced to obtain Γ range of melting points useful for the preparation of an egg made up of these two ingredients. Figure 2 shows the phase diagram, where the useful range consists of lauric acid and monolaurin in a proportion between 3: 2 to 4: 1 by weight.

Esempio 3 - Miscela per ovuli composte da monocaprina e monolaurina Example 3 - Mixture for ova composed of monocaprin and monolaurin

Miscele binarie tra monocaprina e monolaurina sono state prodotte per ottenere P intervallo di punti di fusione utile con il diagramma di fase figura 3, laddove l’intervallo utile è costituito da monocaprina pura fino o in miscela con monolaurina in concentratone massima del 35%. Binary mixtures between monocaprine and monolaurin were produced to obtain P range of useful melting points with the phase diagram in Figure 3, where the useful range consists of pure monocaprin up to or mixed with monolaurin in a maximum concentration of 35%.

Esemnio 4 - Miscela per ovuli composte da acido laurico e acido decilenico Example 4 - Mixture for eggs composed of lauric acid and decylene acid

Miscele binarie tra acido laurico e acido undecileico sono state prodotte per ottenere l’intervallo di punti di fusione, come da diagramma di figura 4, laddove l’ intervallo utile è costituito da acido laurico e acido undecilencio in proporzione tra 4:1 e 3:2 in peso. Binary mixtures between lauric acid and undecylenic acid have been produced to obtain the range of melting points, as shown in the diagram in figure 4, where the useful range consists of lauric acid and undecylencio acid in a proportion between 4: 1 and 3: 2 by weight.

Esempi 5-16 - Ovuli vaginali Examples 5-16 - Vaginal ovules

Gli ingredienti nelle proporzioni indicate nella Tabelle I sono miscelati e fusi a temperatura di circa 40°C, quindi colati in uno stampo per ovuli leggermente raffreddato ed infine separati ad The ingredients in the proportions indicated in Table I are mixed and melted at a temperature of about 40 ° C, then poured into a slightly cooled egg mold and finally separated to

Con analogo metodo si ottengono ovuli con composizione indicata in Tabella I With a similar method, ova with the composition indicated in Table I are obtained

Esempi 17-20 - Capsule molli vaginali Examples 17-20 - Soft vaginal capsules

Gli ingredienti nelle proporzioni indicate nella Tabella Π sono miscelati e fusi a circa 35°C o inferiore. Ciascuna miscela è introdotta in capsula di ge ;atina molle in ciascuna. The ingredients in the proportions indicated in Table II are mixed and melted at about 35 ° C or lower. Each mixture is introduced in soft gelatin capsule into each.

NB Gli acidi grassi utilizzati sono frazioni distillate (98%) di oli vegetali idrolizzati della serie Kortacid™ (Akzo Nobel, Svezia); la monolaurina è Monomuls 90 L (Cognis, D) o “Laurate de glycerol” (Stearinerie Dubiois, F); la monocaprina è: Capmul MCM (C 10) (Abitec Corp, USA) Esempi 21-30 - Test di efficacia in vitro NB The fatty acids used are distilled fractions (98%) of hydrolyzed vegetable oils from the Kortacid ™ series (Akzo Nobel, Sweden); the monolaurin is Monomuls 90 L (Cognis, D) or “Laurate de glycerol” (Stearinerie Dubiois, F); monocaprin is: Capmul MCM (C 10) (Abitec Corp, USA) Examples 21-30 - In vitro efficacy test

Una colonia di C. albicane (2 μΐ) di coltura in 2 mi di YPD è incubata in mezzo di cultura (5 mi) Yeast Peptone-Dextrose (“YPD”) con 10g/l estratto di lievito, 20 g/1 di peptone e 20 g/1 destrosio a 30 °C per 4 ore in beute da 50 mi ad una densità finale di 6,2 logio CFU/ml. A colony of C. albicane (2 μΐ) cultured in 2 ml of YPD is incubated in culture medium (5 ml) Yeast Peptone-Dextrose ("YPD") with 10g / l yeast extract, 20g / 1 peptone and 20 g / 1 dextrose at 30 ° C for 4 hours in 50 ml flasks at a final density of 6.2 logio CFU / ml.

Campioni di cultura (0.5 mi) sono quindi separate e miscelati in presenza delle sostanze test sciolte in etanolo in provette di 14 mi (17x100 mm), con cellule in YPD come controllo. I campioni (100 μΐ) presi al to o dopo 5 h di incubazione a 37 °C sono diluiti x 10 in soluzione fisiologica- Il numero di cellule vitali è valutato pipettando su agar in piastra Sabouraud prelievi di 10μ1 con diluizioni da IO<"2>a IO<"6>e 100 μΐ di IO<"1>. D conteggio delle colonie (CPU) è realizzato dopo 24 ore di incubazione in C02a 37°C, ottenendo un titolo (logi0<5h>) ed il valore Culture samples (0.5 ml) are then separated and mixed in the presence of the test substances dissolved in ethanol in tubes of 14 ml (17x100 mm), with cells in YPD as control. Samples (100 μΐ) taken at or after 5 h of incubation at 37 ° C are diluted x 10 in physiological solution. > at IO <"6> and 100 μΐ of IO <" 1>. D colony count (CPU) is performed after 24 hours of incubation in C02 at 37 ° C, obtaining a titer (logi0 <5h>) and the value

di abbattimento (A logio) per differenza dal controllo (iogio<0>) come illustrato dalla Tabela IV. reduction (A logio) for difference from the control (iogio <0>) as illustrated in Table IV.

Esempi applicativo - Test di efficacia in vivo Application examples - In vivo efficacy test

Un test rapido in agglutinazione su vetrino da tampone vaginale “Candida Bichro-Latex Albicane” (Technogenetics; Sesto SG, MI - 1) con anticorpo monoclonale specifico verso gli antigeni di parete della C albicans è stato utilizzato per valutare Γ attività dell'ovulo dell’es. 5 su una volontaria (36 anni) affetta da candidosi ricorrente. Dal risultato positivo a T°, a seguito di somministrazione locale di 2 ovili/die per 2 settimane si passa ad un risultato negativo. A rapid "Candida Bichro-Latex Albicane" vaginal swab slide agglutination test (Technogenetics; Sesto SG, MI - 1) with monoclonal antibody specific to C albicans wall antigens was used to evaluate Γ activity of the egg cell. 'ex. 5 on a volunteer (36 years old) suffering from recurrent candidiasis. From the positive result at T °, following local administration of 2 sheep / day for 2 weeks we pass to a negative result.

Claims (16)

RIVENDICAZIONI 1. Dispositivo vaginale utile nel trattamento delle vaginosi infettive essenzialmente formato da acid grassi a catena media (MCFA) e/o loro monogliceridi in grado rilasciare una quantità da 6 a 24 mmoli di MCFA-equi valenti. CLAIMS 1. Vaginal device useful in the treatment of infectious vaginosis essentially formed by medium chain fatty acids (MCFA) and / or their monoglycerides capable of releasing a quantity from 6 to 24 mmoles of MCFA-equivalent. 2. Dispositivo secondo la rivendicazione 1 in forma di ovulo vaginale avente punto di fusione compreso tra 31,5 e 37,5°C. 2. Device according to claim 1 in the form of a vaginal ovum having a melting point between 31.5 and 37.5 ° C. 3. Dispositivo secondo le rivendicazioni 1 o 2 dove il MCFA è l’acido capri co. 3. Device according to claims 1 or 2 where the MCFA is capric acid. 4. Dispositivo secondo le rivendicazioni 1 o 2 dove il MCFA è l’acido laurico. 4. Device according to claims 1 or 2 where the MCFA is lauric acid. 5. Dispositivo secondo le rivendicazioni 1 o 2 dove detto monogliceride è la monolaurina. 5. Device according to claims 1 or 2 wherein said monoglyceride is monolaurin. 6. Dispositivo secondo le rivendicazioni 1 o 2 dove detto monogliceride è la monocaprina. 6. Device according to claims 1 or 2 wherein said monoglyceride is monocaprin. 7. Dispositivo secondo le rivendicazioni 1-6 contenente almeno un MCFA scelto tra acido caprico e acido laurico ed almeno un monogliceride scelto tra monocaprina e monolaurina. 7. Device according to claims 1-6 containing at least one MCFA selected from capric acid and lauric acid and at least one monoglyceride selected from monocaprin and monolaurin. 8. Dispositivo secondo una o più delle rivendicazioni 1-6 comprendente: (a) uno o più MCFA o suo monogliceride; (b) uno o più lipide C8-C12 non-irritante scelto tra: (bl) un carbossilato C8-C12 insaturo e/o ramificato; (b2) un acido idrossammico C8-C12; (b4) un aldeide C8-C12 satura o insatura, lineare o ramificata; (b5) un estere gallico di un alcol C8-C12 saturo o insaturo, lineare o ramificato; detto dispositivo in grado rilasciare una quantità da 6 a 24 mmoli di MCFA-equivalenti in forma di ovulo o di capsula di gelatina molle. 8. Device according to one or more of claims 1-6 comprising: (a) one or more MCFAs or its monoglyceride; (b) one or more non-irritating C8-C12 lipids chosen from: (b1) an unsaturated and / or branched C8-C12 carboxylate; (b2) a C8-C12 hydroxamic acid; (b4) a saturated or unsaturated, linear or branched C8-C12 aldehyde; (b5) a gallic ester of a saturated or unsaturated, linear or branched C8-C12 alcohol; said device capable of releasing a quantity from 6 to 24 mmoles of MCFA-equivalents in the form of an egg or a soft gelatin capsule. 9. Dispositivo secondo una o più delle rivendicazioni 1-6 comprendente: (a) uno o più MCFA o suo monogliceride, (b’) uno più terpene o (alchil)fenolo non-irritante scelto tra: (b’1) un terpene a funzione alcolica; (b’2) un terpene a Unzione carbonilica; (b’3) un terpene (ciclo)alifatico saturo o insaturo; (b’4) un fenolo compreso nell’elenco degli aromi; (b’5) un ossialchilbenzene compreso nell’elenco degli aromi; detto dispositivo in grado rilasciare una quantità da 6 a 24 mmoli di MCFA-equivalenti in forma di ovulo o di capsula di gelatina molle. 9. Device according to one or more of claims 1-6 comprising: (a) one or more MCFAs or its monoglyceride, (b ') one plus non-irritating terpene or (alkyl) phenol chosen from: (b1) a terpene with an alcoholic function; (b'2) a carbonyl unction terpene; (b'3) a saturated or unsaturated aliphatic terpene (cycle); (b'4) a phenol included in the list of flavors; (b'5) an oxyalkylbenzene included in the list of flavors; said device capable of releasing a quantity from 6 to 24 mmoles of MCFA-equivalents in the form of an egg or a soft gelatin capsule. 10. Dispositivo secondo la rivendicazione 9 dove detti (b’) sono apportati da un olio essenziale. 10. Device according to claim 9 where said (b ') are provided by an essential oil. 11. Dispositivo secondo la rivendicazione 10 dove Folio essenziale è scelto tra olio di lavanda, eucaliptolo, tea tree oil o tra oli essenziali contenenti carvacrolo e cimenolo come Folio di maggiorana, origano, santoreggia o timo. 11. Device according to claim 10 wherein the essential oil is selected from lavender oil, eucalyptol, tea tree oil or from essential oils containing carvacrol and cimenol such as marjoram, oregano, savory or thyme. 12. Dispositivo secondo una o più delle rivendicazioni 1-6 comprendente: (a) uno o più MCFA o suo monogliceride; (b”) un antimi corico/ antibiotico; detto dispositivo in grado rilasciare una quantità da 6 a 24 mmoli di MCFA-equivalenti, nel quale F antimi cotico (b”) è presente in quantità sub-inibitoria (pari a circa la metà del dosaggio corrente), detto dispositivo in forma di ovulo o di capsula di gelatina molle. Device according to one or more of claims 1-6 comprising: (a) one or more MCFAs or its monoglyceride; (b ”) an antimicrobial / antibiotic; said device capable of releasing a quantity from 6 to 24 mmoles of MCFA-equivalents, in which the antimicotic (b ") is present in a sub-inhibitory quantity (equal to about half the current dosage), said device in the form of an egg or soft gelatin capsule. 13. Dispositivo secondo le rivendicazioni 8 e 9 comprendente (a), (b) e (b’). 13. Device according to claims 8 and 9 comprising (a), (b) and (b '). 14. Dispositivo secondo le rivendicazioni 8 e 12 comprendente (a), (b) e (b”). 14. Device according to claims 8 and 12 comprising (a), (b) and (b "). 15. Dispositivo secondo le rivendicazioni 9 e 12 comprendente (a), (b’) e (b”). 15. Device according to claims 9 and 12 comprising (a), (b ') and (b "). 16. Metodo di produzione di un ovulo vaginale secondo una o più delle rivendicazioni 2-15 precedenti mediante miscelazione di MCFA e/o monogliceridi, da soli o in combinazione, eventualmente parzialmente neutralizzati, opzionalmente con uno o più tra (b), (b<’>) e (b!) e una quantità minore (<30%) di ingredienti addizionali, ad ottenere una ovulo con p.f. compreso tra 31,5 e 37,5°C, preferibilmente tra 32 e 36°C.16. Method of producing a vaginal ovum according to one or more of the preceding claims 2-15 by mixing MCFA and / or monoglycerides, alone or in combination, optionally partially neutralized, optionally with one or more of (b), (b <'>) and (b!) and a minor amount (<30%) of additional ingredients, to obtain an egg with m.p. between 31.5 and 37.5 ° C, preferably between 32 and 36 ° C.
ITMI20070084 2007-01-22 2007-01-22 LIPID BASED VAGINAL ANTISEPTIC DEVICES ITMI20070084A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITMI20070084 ITMI20070084A1 (en) 2007-01-22 2007-01-22 LIPID BASED VAGINAL ANTISEPTIC DEVICES
PCT/IB2008/000135 WO2008090440A1 (en) 2007-01-22 2008-01-22 Lipid-based gynaecologic suppository

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20070084 ITMI20070084A1 (en) 2007-01-22 2007-01-22 LIPID BASED VAGINAL ANTISEPTIC DEVICES

Publications (1)

Publication Number Publication Date
ITMI20070084A1 true ITMI20070084A1 (en) 2008-07-23

Family

ID=39434152

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI20070084 ITMI20070084A1 (en) 2007-01-22 2007-01-22 LIPID BASED VAGINAL ANTISEPTIC DEVICES

Country Status (2)

Country Link
IT (1) ITMI20070084A1 (en)
WO (1) WO2008090440A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2215913A1 (en) 2009-01-23 2010-08-11 Nutreco Nederland B.V. Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
AU2012398334B2 (en) 2012-12-27 2018-04-26 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
BR112015013756B1 (en) 2012-12-27 2021-07-20 Kimberly-Clark Worldwide, Inc. METHOD OF ADJUSTING THE SOLUBILITY OF A BOTANICAL OIL IN WATER, BOTANICAL OIL, SCARF, AND, ABSORBING ARTICLE
CN104856942B (en) * 2015-06-04 2017-09-26 烟台荣昌制药股份有限公司 Ciclopirox olamine vaginal dilation bolt and its preparation method
EP3972560A4 (en) * 2019-05-23 2023-08-09 Bio-Bee Sde Eliyahu Ltd Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth
CN114315586B (en) * 2021-12-23 2023-12-08 江苏浩丰生物科技有限公司 Acacia vanillate and preparation method and application thereof in tobacco industry

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002775A (en) * 1973-07-09 1977-01-11 Kabara Jon J Fatty acids and derivatives of antimicrobial agents
GB1544576A (en) * 1976-07-12 1979-04-19 Kali Chemie Pharma Gmbh Enterally highly-absorbable preparations of cardiac glycosides which by themselves are absorbable with difficulty and process for the production of such preparations
JPS5857407B2 (en) * 1980-03-19 1983-12-20 京都薬品工業株式会社 Base for rectal administration
DE3204124A1 (en) * 1982-02-06 1983-08-18 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC TAMPONS WITH HIGH ACTIVE SUBSTANCE RELEASE
WO1991013601A1 (en) * 1990-03-15 1991-09-19 Rhône-Poulenc Rorer International (Holdings) Inc. Calcitonin suppository formulations
US20050043402A1 (en) * 1996-11-14 2005-02-24 Halldor Thormar Methods and formulations for counteracting infection of mucosa or skin
EP1319397B1 (en) * 2000-09-21 2005-08-17 Taisho Pharmaceutical Co., Ltd Suppositories sustained in the lower rectum
WO2006029818A2 (en) * 2004-09-16 2006-03-23 Dsm Ip Assets B.V. Cosmetic compositions containing an hydroxamic acid compound optionally in combination with a retinoid

Also Published As

Publication number Publication date
WO2008090440A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
ITMI20070084A1 (en) LIPID BASED VAGINAL ANTISEPTIC DEVICES
Fernandes Costa et al. Development, characterization, and in vitro–in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis
EP2497459B1 (en) Methods of reducing microbial contamination
US8476319B2 (en) Methods of treating ear infections
Palmeira-de-Oliveira et al. New strategies for local treatment of vaginal infections
Amaral et al. Amphotericin B in poly (lactic-co-glycolic acid)(PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis
Zia et al. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans
CA2843431A1 (en) Sandalwood oil and its uses related to skin disorders
Abadi et al. Silver nanoparticles as active ingredient used for alcohol-free mouthwash
Clitherow et al. Medium-chain fatty acids released from polymeric electrospun patches inhibit Candida albicans growth and reduce the biofilm viability
Lin et al. Cationic amphiphile in phospholipid bilayer or oil–water interface of nanocarriers affects planktonic and biofilm bacteria killing
Costa et al. Farnesol: An approach on biofilms and nanotechnology
Faergemann et al. A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism
Santoro Topical therapy for canine pyoderma: what is new?
Tangsuksan et al. Antimicrobial and anti-inflammatory effects of α-mangostin soluble film
Sailaja et al. Comparative Evaluation of Various Herbal and Synthetic Solutions On Disinfection Of Guttapercha: An: In Vitro: Study
Negi et al. Essential oil and nanocarrier-based formulations approaches for vaginal candidiasis
EP0310476B1 (en) Inhibitory or destructible composition of at least one unicellular living being containing fluor f- and lithium li+
Manzoor et al. Nanosizing of Lavender, Basil, and Clove Essential Oils into Microemulsions for Enhanced Antioxidant Potential and Antibacterial and Antibiofilm Activities
AU2009329084A1 (en) A novel dermaceutical cream made using Sodium Fusidate
Bowe et al. Solodyn and updates on topical and oral therapies for acne
US20240065998A1 (en) Monoacylglycerol and free fatty acid-based compositions, methods of manufacturing and use of the same
Rolim et al. Essential Oil Encapsulated in Nanoparticles for Treatment of Skin Infections
Jalili et al. Pure Thymol, and its Nanoliposome and Nanoparticle Forms, Inhibit Trichomonas vaginalis Infection in Culture
US20220054411A1 (en) Multiple concentrate formulation for medical products